Pradaxa® Multi District Litigation
According to a news update, Boehringer Ingelheim, the manufacturer of the anticoagulant Pradaxa®, is the target of a lawsuit over allegations that the drug leads to severe internal bleeding. One of the plaintiffs in this lawsuit – which is now part of the Pradaxa® MDL pending in the Southern District of Illinois – Robert Connelly, was prescribed Pradaxa® in May of 2011. By September, he found himself in the hospital for serious gastrointestinal bleeding. During his five-day stay, Connelly received a transfusion of five units of blood, a colonoscopy, and esophagogastroduodenoscopy (EGD).
Pradaxa® is an oral anticoagulant (blood thinner) that often acts as an alternative to Warfarin®. Pradaxa® is associated with a number of adverse effects, such as kidney failure, hemorrhagic stroke, and most notably, excessive bleeding, which can lead to death. There have been over 500 deaths linked to Pradaxa® bleeding complications.
Lawsuits continue to be filed against Boehringer Ingelheim for complications associated with Pradaxa®. If you or a loved one has suffered such complications, contact the experienced pharmaceutical attorneys at Schlichter, Bogard & Denton, LLP toll-free at 1-800-873-5297 for a free, confidential consultation.
Legal Disclaimer: The choice of a lawyer is an important decision and should not be based solely on advertisements.